在确定共价表皮生长因子受体抑制剂的效能和突变选择性方面的陷和考虑
Kristopher W Hoyt1, Daniel A Urul2, Blessing C Ogboo1
1Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, New York 14260, United States.
Journal of medicinal chemistry
|December 22, 2023
概括
协同抑制剂,像那些向表皮生长因子受体 (EGFR) 的药物一样,需要专门的依赖时间的测试. 这项研究提供了对测定方法和动力学值的指导,以提高共价药物开发的可靠性.
科学领域:
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
- 药理学 药理学是指药理学的学科.
背景情况:
- 共价抑制剂在药物开发中越来越重要.
- 评估它们的活性需要复杂的依赖时间的测定,与可逆抑制剂不同.
- 可靠的动力学数据对于开发有效的共价药物至关重要.
研究的目的:
- 为评估共价抑制剂生物化学活性的方法提供指导.
- 报告共价表皮生长因子受体 (EGFR) 抑制剂的动力值和实验因子.
- 在共价药物设计中提高试验可靠性和可重复性.
主要方法:
- 探索测定方法,以确定共价EGFR抑制剂的生物化学活性.
- 分析液体处理和测试试剂如何影响动力参数和功效的分析.
- 包括使用参考抑制剂的基准动力学值.
主要成果:
- 液体处理和试剂显著影响动力参数和功率解释.
- 在文献中,共价EGFR抑制剂的动力学值不一致是普遍存在的.
- 对参考抑制剂提供的基准数据.
结论:
- 这项研究为开发新的共价抑制剂提供了最佳实践信息.
- 解决知识差距对于提高测试可靠性和可重复性至关重要.
- 了解测试影响对于共价药物设计中的结构动力学关系至关重要.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
8.6K
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
